Uncoupling environmental pH and intrabacterial acidification from pyrazinamide susceptibility in Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 12, 2015, Pages 7320-7326

  Peterson, Nicholas D ^a,b   Rosen, Brandon C ^a   Dillon, Nicholas A ^a   Baughn, Anthony D ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; GREEN FLUORESCENT PROTEIN; IONOPHORE; MONENSIN; PYRAZINAMIDE; AMIDASE; CARBONYL 3-CHLOROPHENYLHYDRAZONE; HYDRAZONE DERIVATIVE; PNCA PROTEIN, MYCOBACTERIUM TUBERCULOSIS; PROTON; PROTON IONOPHORE; PYRAZINOIC ACID; TUBERCULOSTATIC AGENT;

ACIDIFICATION; ALKALINITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CONTROLLED STUDY; ENVIRONMENT; GENE OVEREXPRESSION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; STANDARD; WILD TYPE; ANALOGS AND DERIVATIVES; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; PH; REPORTER GENE;

AMIDOHYDROLASES; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HYDRAZONES; HYDROGEN-ION CONCENTRATION; MICROBIAL SENSITIVITY TESTS; MONENSIN; MYCOBACTERIUM TUBERCULOSIS; PROTON IONOPHORES; PROTONS; PYRAZINAMIDE;

EID: 84954539106     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00967-15     Document Type: Article

References (39)

1. Anonymous. 1981. A controlled trial of six months chemotherapy in pulmonary tuberculosis. First report: results during chemotherapy. British Thoracic Association. Br J Dis Chest 75:141-153.
2. Anonymous. 2014. Global tuberculosis report 2014. World Health Organization, Geneva, Switzerland.
3. Scorpio A, Zhang Y. 1996. Mutations in pncA, a gene encoding pyrazinamidase/ nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med 2:662-667. http://dx.doi.org /10.1038/nm0696-662.
4. Konno K, Feldmann FM, McDermott W. 1967. Pyrazinamide susceptibility and amidase activity of tubercle bacilli. Am Rev Respir Dis 95:461-469.
5. Boshoff HIM, Xu X, Tahlan K, Dowd CS, Pethe K, Camacho LR, Park T-H, Yun C-S, Schnappinger D, Ehrt S, Williams KJ, Barry CE. 2008. Biosynthesis and recycling of nicotinamide cofactors in Mycobacterium tuberculosis: an essential role for NAD in nonreplicating bacilli. J Biol Chem 283:19329-19341. http://dx.doi.org/10.1074/jbc.M800694200.
6. Vilchèze C, Weinrick B, Wong K-W, Chen B, Jacobs WR, Jr. 2010. NAD(+) auxotrophy is bacteriocidal for the tubercle bacilli. Mol Microbiol 76:365-377. http://dx.doi.org/10.1111/j.1365-2958.2010.07099.x.
7. Zhang Y, Shi W, Zhang W, Mitchison D. 2013. Mechanisms of pyrazinamide action and resistance. Microbiol Spectr 2:MGM2-0023-2013. http://dx.doi.org/10.1128/microbiolspec.MGM2-0023-2013.
8. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, Wang H, Zhang W, Zhang Y. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630-1632. http://dx.doi.org/10.1126 /science.1208813.
9. Dillon NA, Peterson ND, Rosen BC, Baughn AD. 2014. Pantothenate and pantetheine antagonize the antitubercular activity of pyrazinamide. Antimicrob Agents Chemother 58:7258-7263. http://dx.doi.org/10.1128 /AAC.04028-14.
10. Shi W, Chen J, Feng J, Cui P, Zhang S, Weng X, Zhang W, Zhang Y. 2014. Aspartate decarboxylase (PanD) as a new target of pyrazinamide in Mycobacterium tuberculosis. Emerg Microbes Infect 3:e58. http://dx.doi.org/10.1038/emi.2014.61.
11. Zhang S, Chen J, Shi W, Liu W, Zhang W, Zhang Y. 2013. Mutations in panD encoding aspartate decarboxylase are associated with pyrazinamide resistance in Mycobacterium tuberculosis. Emerg Microbes Infect 2:e34. http://dx.doi.org/10.1038/emi.2013.38.
12. Anonymous. 1974. Controlled clinical trial of four short-course (6-month) regimens of pulmonary tuberculosis: third report. East African/ British Medical Research Councils. Lancet 2:237-240.
13. Dessau FI, Yeager RL, Burger FJ, Williams JH. 1952. Pyrazinamide (aldinamide) in experimental tuberculosis of the guinea pig. Am Rev Tuberc 65:519-522.
14. Yeager RL, Munroe WG, Dessau FI. 1952. Pyrazinamide (aldinamide) in the treatment of pulmonary tuberculosis. Am Rev Tuberc 65:523-546.
15. Malone LSA, Lindh H, McKenzie D, Kiser JS, Williams JH. 1952. The effect of pyrazinamide (aldinamide) on experimental tuberculosis in mice. Am Rev Tuberc 65:511-518.
16. Tarshis M, Weed WJ. 1953. Lack of significant in vitro sensitivity of Mycobacterium tuberculosis to pyrazinamide on three different solid media. Am Rev Tuberc 67:391-395.
17. McDermott W, Tompsett R. 1954. Activation of pyrazinamide and nicotinamide in acidic environments in vitro. Am Rev Tuberc 70:748-754.
18. Zhang Y, Scorpio A, Nikaido H, Sun Z. 1999. Role of acid pH and deficient efflux of pyrazinoic acid in unique susceptibility of Mycobacterium tuberculosis to pyrazinamide. J Bacteriol 181:2044-2049.
19. Huang Q, Chen Z-F, Li Y-Y, Zhang Y, Ren Y, Fu Z, Xu S-Q. 2007. Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. Chemotherapy 53:338-343. http://dx.doi.org/10.1159/000107723.
20. Chen Z-F, Huang Q, Li Y-Y, Zhang Y, Ren Y, Li K-S, Fu Z, Xu S-Q. 2007. Nutrient-starved incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 30:359-362.
21. Wade MM, Zhang Y. 2004. Anaerobic incubation conditions enhance pyrazinamide activity against Mycobacterium tuberculosis. J Med Microbiol 53:769-773. http://dx.doi.org/10.1099/jmm.0.45639-0.
22. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. 2003. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 52: 790-795. http://dx.doi.org/10.1093/jac/dkg446.
23. Zimhony O, Cox JS, Welch JT, Vilchèze C, Jacobs WR, Jr. 2000. Pyrazinamide inhibits the eukaryotic-like fatty acid synthetase I (FASI) of Mycobacterium tuberculosis. Nat Med 6:1043-1047. http://dx.doi.org/10.1038/79558.
24. Miotto P, Cirillo DM, Migliori GB. 2015. Drug resistance in Mycobacterium tuberculosis: molecular mechanisms challenging fluoroquinolones and pyrazinamide effectiveness. Chest 147:1135-1143. http://dx.doi.org /10.1378/chest.14-1286.
25. Heifets L. 2002. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 51:11-12. http://dx.doi.org/10.1099/0022-1317-51-1-11.
26. Vandal OH, Pierini LM, Schnappinger D, Nathan CF, Ehrt S. 2008. A membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium tuberculosis. Nat Med 14:849-854. http://dx.doi.org/10.1038 /nm.1795.
27. Zhang Y, Permar S, Sun Z. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 51:42-49. http://dx.doi.org/10.1099/0022-1317-51-1-42.
28. Baughn AD, Deng J, Vilcheze C, Riestra A, Welch JT, Jacobs WR, Jr, Zimhony O. 2010. Mutually exclusive genotypes for pyrazinamide and 5-chloropyrazinamide resistance reveal a potential resistance-proofing strategy. Antimicrob Agents Chemother 54:5323-5328. http://dx.doi.org /10.1128/AAC.00529-10.
29. Eoh H, Rhee KY. 2013. Multifunctional essentiality of succinate metabolism in adaptation to hypoxia in Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 110:6554-6559. http://dx.doi.org/10.1073/pnas.1219375110.
30. Ehrt S, Guo XV, Hickey CM, Ryou M, Monteleone M, Riley LW, Schnappinger D. 2005. Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor. Nucleic Acids Res 33:e21. http://dx.doi.org/10.1093/nar/gni013.
31. Boshoff HIM, Mizrahi V. 2000. Expression of Mycobacterium smegmatis pyrazinamidase in Mycobacterium tuberculosis confers hypersensitivity to pyrazinamide and related amides. J Bacteriol 182:5479-5485. http://dx.doi.org/10.1128/JB.182.19.5479-5485.2000.
32. Miesenbock G, De Angelis DA, Rothman JE. 1998. Visualizing secretion and synaptic transmission with pH-sensitive green fluorescent proteins. Nature 394:192-195. http://dx.doi.org/10.1038/28190.
33. Kasianowicz J, Benz R, McLaughlin S. 1984. The kinetic mechanism by which CCCP (carbonyl cyanidem-chlorophenylhydrazone) transports protons across membranes. J Membr Biol 82:179-190. http://dx.doi.org /10.1007/BF01868942.
34. Huczyński A, Janczak J, Łowicki D, Brzezinski B. 2012. Monensin A acid complexes as a model of electrogenic transport of sodium cation. Biochim Biophys Acta 1818:2108-2119. http://dx.doi.org/10.1016/j.bbamem.2012.04.017.
35. Russell JB. 1991. Resistance of Streptococcus bovis to acetic acid at low pH: relationship between intracellular pH and anion accumulation. Appl Environ Microbiol 57:255-259.
36. Lee JS, Krause R, Schreiber J, Mollenkopf H-J, Kowall J, Stein R, Jeon B-Y, Kwak J-Y, Song M-K, Patron JP, Jorg S, Roh K, Cho S-N, Kaufmann SHE. 2008. Mutation in the transcriptional regulator PhoP contributes to avirulence of Mycobacterium tuberculosis H37Ra strain. Cell Host Microbe 3:97-103. http://dx.doi.org/10.1016/j.chom.2008.01.002.
37. Baker JJ, Johnson BK, Abramovitch RB. 2014. Slow growth of Mycobacterium tuberculosis at acidic pH is regulated by phoPR and host-associated carbon sources. Mol Microbiol 94:56-69. http://dx.doi.org/10.1111/mmi.12688.
38. Darby CM, Ingólfsson HI, Jiang X, Shen C, Sun M, Zhao N, Burns K, Liu G, Ehrt S, Warren JD, Anderson OS, Brickner SJ, Nathan C. 2013. Whole cell screen for inhibitors of pH homeostasis in Mycobacterium tuberculosis. PLoS One 8:e68942. http://dx.doi.org/10.1371/journal.pone.0068942.
39. Lu P, Haagsma AC, Pham H, Maaskant JJ, Mol S, Lill H, Bald D. 2011. Pyrazinoic acid decreases the proton motive force, respiratory ATP synthesis activity, and cellular ATP levels. Antimicrob Agents Chemother 55:5354-5357. http://dx.doi.org/10.1128/AAC.00507-11.